Back to today’s briefing

Story perspectives

Zanzalintinib-Atezolizumab Combo Boosts Survival in Colorectal Cancer

6/26/2025

50 7

Summary

Story summary

The STELLAR-303 trial demonstrated that zanzalintinib combined with atezolizumab enhances overall survival in metastatic colorectal cancer versus regorafenib.
No new safety issues emerged; the safety profile remained consistent with earlier studies.
The trial included 901 participants and will further evaluate outcomes for patients without liver metastases.
Comprehensive results are set to be shared at an upcoming medical conference.

1 of 1

Story summary

The STELLAR-303 trial demonstrated that zanzalintinib combined with atezolizumab enhances overall survival in metastatic colorectal cancer versus regorafenib.
No new safety issues emerged; the safety profile remained consistent with earlier studies.
The trial included 901 participants and will further evaluate outcomes for patients without liver metastases.
Comprehensive results are set to be shared at an upcoming medical conference.